An 11-amino-acid EPO-derived peptide studied for tissue-protective and neuropathic repair signaling without erythropoiesis.
Pre-loaded with a typical ARA-290 vial. Change any value to match what you actually have.
What published research and laboratory protocols actually document for ARA-290. Where a compound has no single microgram figure, we say so rather than inventing one.
| Reported amount | Frequency | Route | Where this figure comes from |
|---|---|---|---|
| 1 mg – 8 mg | daily | subcutaneous | Phase 2 dose-ranging SC trial in sarcoidosis-associated small-fiber neuropathy Published arms included 1, 4, and 8 mg/day SC for 28 days; 4 mg was frequently discussed as the most favorable overall profile in that study. |
| 4 mg | daily | subcutaneous | Diabetic macular edema phase 2 pilot Self-administered 4 mg/day SC for 12 weeks under trial conditions. |
People searching this page also look for: ara 290 peptide dosage, ara 290 peptide dosage per day, ara-290 peptide dosage, ara 290 peptide dosage chart, ara-290 peptide dosage per day.
ARA-290, also known as cibinetide, is an 11-residue peptide modeled on the helix-B surface of erythropoietin. Researchers designed it to engage the innate repair receptor complex associated with tissue protection and anti-inflammatory signaling while avoiding the erythropoietic activity of full-length EPO.
Clinical research has focused on small-fiber neuropathy contexts (including sarcoidosis-associated disease), painful diabetic neuropathy endpoints, and exploratory diabetic macular edema work. Dose-ranging subcutaneous studies compared daily milligram-level exposures over weeks, with 4 mg daily often highlighted in published summaries.
ARA-290 is an investigational research peptide, not a general wellness injectables staple. Educational dosage figures below summarize documented trial exposures for literature navigation only.
Cibinetide is understood to activate the innate repair receptor, a complex involving EPOR and β-common receptor components distinct from the classical homodimeric EPO receptor that drives red-cell production. Downstream signaling is studied for anti-inflammatory, neuroprotective, and tissue-repair programs. Because erythropoiesis is not the intended pathway, hematologic safety monitoring in trials has been an important differentiator from EPO itself.
small-fiber neuropathy research · sarcoidosis neurologic complications · diabetic neuropathy models · diabetic macular edema exploratory research · innate repair receptor pharmacology
Neurology, ophthalmology, and inflammation-biology groups working on non-hematopoietic EPO signaling are the main research audience. Neuropathic-pain trialists and corneal-nerve imaging labs also appear in the author lists of key papers.
Lyophilized ARA-290/cibinetide research material is stored cold and dry per COA. Reconstituted solution is refrigerated; trial products followed protocol-specific stability instructions.
Published programs generally evaluate cibinetide as monotherapy on top of standard care for the underlying condition. Mechanistic literature compares it with EPO and other tissue-protective EPO mimetics rather than with common gym-peptide stacks. Combination rationale, when discussed, is pathway-level (repair signaling vs erythropoiesis), not informal stacking culture.
The questions people actually search for, answered plainly.
Human trials most often used 1–8 mg subcutaneously once daily, with 4 mg daily appearing repeatedly across neuropathy and ocular pilot work. Those are documented clinical-research doses.
Depends on vial mass. A 5 mg vial in 1 mL bacteriostatic water yields 5 mg/mL (50 units on a U-100 syringe = 2.5 mg). Labs choose diluent volume to match the protocol’s milligram increments.
Daily subcutaneous administration for about 28 days is the dominant published neuropathy schedule; one ocular pilot extended daily dosing to 12 weeks.
A literature chart should list 1 mg, 4 mg, and 8 mg daily SC arms from dose-ranging work, plus the 4 mg daily DME pilot. Include duration (28 days vs 12 weeks) beside the mg amount.
Detailed consumer-facing half-life numbers are less prominent than dose-response outcomes in abstracts; clinically studied regimens used once-daily SC dosing, implying a practical need for daily exposure in those designs.
Trials typically studied cibinetide alone plus standard disease therapy. Experimental combinations should stay inside controlled research protocols.
No. It is a short EPO-derived peptide engineered toward tissue-protective innate-repair signaling without stimulating red-blood-cell production the way EPO does.
Cibinetide is the international nonproprietary name used in later clinical publications; ARA-290 is the earlier research code.
Primary literature on ARA-290. Open access where available.
Every citation above was programmatically checked against the NCBI PubMed database. Titles shown are the official indexed titles, not paraphrases.
Our support assistant walks through reconstitution, syringe units, storage, and how to read a Certificate of Analysis. Free, no account.
Read the guides